

Summary under Regulation 13 (1)(B) of the Combination Regulations

A summary of the combination, not containing any confidential information, in not more than 500 words, comprising details regarding (a) name of the parties to the combination; (b) the type of the combination; (c) the area of activity of the parties to the combination; and (d) the relevant market(s) to which the combination relates.

A. Name of the parties to the combination

1. Allergan plc (**Allergan**); Pfizer Inc. (**Pfizer**); and Watson Merger Sub Inc. (**Merger Sub**)

B. Type of the Combination

2. This Form II notification is being filed with the Hon'ble Competition Commission of India in accordance with Section 6(2) of the Competition Act, 2002, jointly by Allergan, Pfizer and Merger Sub.
3. Pursuant to the proposed transaction, Merger Sub, a newly incorporated wholly owned subsidiary of Allergan will merge with and into Pfizer, a corporation incorporated under the laws of the State of Delaware, U.S.A. As a result, Pfizer will become a wholly owned subsidiary of Allergan and Allergan will be renamed as Pfizer plc.

C. Area of the activity of the parties to the combination

4. Allergan is a global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of brand name, generic, branded generic, biosimilar, and over-the-counter pharmaceutical products.
5. Pfizer is a global research-based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing, and selling innovative medicines for humans.
6. Merger Sub is a newly incorporated entity, and is not engaged in any business activities.

D. Relevant market(s) to which the combination relates

7. On the basis of the Anatomical Therapeutic Chemical (ATC) 3 classification and data from Intercontinental Medical Services (IMS), the Parties have overlaps only in the following product categories in India, (a) Ophthalmological Anti-infectives (S1A), (b) Miotics and Anti-glaucoma preparations (S1E); and (c) Artificial Tears and Ocular lubricants (S1K).